| CASE SERIES REPORT |
|
| Year : 2022 | Volume
: 66
| Issue : 1 | Page : 83-85 |
|
|
Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant)
Anupa Mary Job1, Bindurani Sudhamani2, Manju Mohan1, SN Mohanasundaram3
1 Assistant Professor, Department of Dermatology, GMC, Palakkad, Kerala, India
2 Associate Professor and HOD, Department of Dermatology, GMC, Palakkad, Kerala, India
3 Junior Resident, Department of Dermatology, GMC, Palakkad, Kerala, India
Correspondence Address:
Anupa Mary Job
“Madhootty House”, Palace Buildings, GB Road, Palakkad - 678 001, Kerala
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijph.ijph_2017_21
|
|
|
Ever since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, science has unraveled much knowledge on SARS-CoV-2 which has led to extraordinary and unprecedented progress in developing COVID-19 vaccines. Several adverse cutaneous reactions, ranging from more common local injection site reaction, neutrophilic and pustular drug reactions to flare-up of preexisting dermatoses, have been reported with currently available vaccines. We report a case series of 7 patients who developed herpes zoster (HZ) following the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (recombinant). HZ following vaccination is a rare entity. The occurrence of HZ in the patients presented in this series within the time window 1–21 days after vaccination defined for increased risk and postulated dysregulation of T-cell-mediated immunity, suggests that the ChAdOx1 nCoV-19 coronavirus vaccine (recombinant) could probably be a trigger for reactivation of varicella zoster virus to cause HZ in them.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
